Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia

27 Nov 2013

Abstract excerpt

Despite advances in allogeneic stem cell transplantation, BCR-ABL-positive acute lymphoblastic leukaemia (ALL) remains a high-risk disease, necessitating the development of novel treatment strategies. As the known oncomir, miR-17~92, is regulated by BCR-ABL fusion in chronic myeloid leukaemia, we investigated its role in BCR-ABL translocated ALL. miR-17~92-encoded miRNAs were significantly less abundant in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Chronic Myeloid Leukemia Treatments
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24280866
DOI: 10.1038/leu.2013.361

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemiaPMID 24280866Read ↗

The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loopSemantic proximity Read ↗

Apoptosis of B-cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimeticSemantic proximity Read ↗

The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignanciesSemantic proximity Read ↗

Prognostic Value of the miR-17~92 Cluster in Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemiaSemantic proximity Read ↗

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92Semantic proximity Read ↗

Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemiaSemantic proximity Read ↗

Antagomir-17-5p Abolishes the Growth of Therapy-Resistant Neuroblastoma through p21 and BIMSemantic proximity Read ↗

A microRNA polycistron as a potential human oncogene.Semantic proximity Read ↗

Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.Semantic proximity Read ↗

miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma.Semantic proximity Read ↗

Bcl‐2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT‐737, ABT‐263 and ABT‐199 by impeding direct bindingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.